Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson’s Disease Project

Archive ouverte

Vollstedt, Eva-Juliane | Madoev, Harutyun | Aasly, Anna | Ahmad-Annuar, Azlina | Al-Mubarak, Bashayer | Alcalay, Roy, N | Alvarez, Victoria | Amorin, Ignacio | Annesi, Grazia | Arkadir, David | Bardien, Soraya | Barker, Roger, A | Barkhuizen, Melinda | Basak, A. Nazli | Bonifati, Vincenzo | Boon, Agnita | Brighina, Laura | Brockmann, Kathrin | Carmine Belin, Andrea | Carr, Jonathan | Clarimon, Jordi | Cornejo-Olivas, Mario | Correia Guedes, Leonor | Corvol, Jean-Christophe | Crosiers, David | Damásio, Joana | Das, Parimal | de Carvalho Aguiar, Patricia | de Rosa, Anna | Dorszewska, Jolanta | Ertan, Sibel | Ferese, Rosangela | Ferreira, Joaquim | Gatto, Emilia | Genç, Gençer | Giladi, Nir | Gómez-Garre, Pilar | Hanagasi, Hasmet | Hattori, Nobutaka | Hentati, Faycal | Hoffman-Zacharska, Dorota | Illarioshkin, Sergey, N | Jankovic, Joseph | Jesús, Silvia | Kaasinen, Valtteri | Kievit, Anneke | Klivenyi, Peter | Kostic, Vladimir | Koziorowski, Dariusz | Kühn, Andrea, A | Lang, Anthony, E | Lim, Shen-Yang | Lin, Chin-Hsien | Lohmann, Katja | Markovic, Vladana | Martikainen, Mika Henrik | Mellick, George | Merello, Marcelo | Milanowski, Lukasz | Mir, Pablo | Öztop-Çakmak, Özgür | Pimentel, Márcia Mattos Gonçalves | Pulkes, Teeratorn | Puschmann, Andreas | Rogaeva, Ekaterina | Sammler, Esther, M | Skaalum Petersen, Maria | Skorvanek, Matej | Spitz, Mariana | Suchowersky, Oksana | Tan, Ai Huey | Termsarasab, Pichet | Thaler, Avner | Tumas, Vitor | Valente, Enza Maria | van de Warrenburg, Bart | Williams-Gray, Caroline, H | Wu, Ruey-Mei | Zhang, Baorong | Zimprich, Alexander | Solle, Justin | Padmanabhan, Shalini | Klein, Christine

Edité par CCSD ; Public Library of Science -

International audience. Parkinson’s disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk factor. However, the vast majority of our present data on monogenic PD is based on the investigation of patients of European White ancestry, leaving a large knowledge gap on monogenic PD in underrepresented populations. Gene-targeted therapies are being developed at a fast pace and have started entering clinical trials. In light of these developments, building a global network of centers working on monogenic PD, fostering collaborative research, and establishing a clinical trial-ready cohort is imperative. Based on a systematic review of the English literature on monogenic PD and a successful team science approach, we have built up a network of 59 sites worldwide and have collected information on the availability of data, biomaterials, and facilities. To enable access to this resource and to foster collaboration across centers, as well as between academia and industry, we have developed an interactive map and online tool allowing for a quick overview of available resources, along with an option to filter for specific items of interest. This initiative is currently being merged with the Global Parkinson’s Genetics Program (GP2), which will attract additional centers with a focus on underrepresented sites. This growing resource and tool will facilitate collaborative research and impact the development and testing of new therapies for monogenic and potentially for idiopathic PD patients.

Suggestions

Du même auteur

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

Archive ouverte | Vollstedt, Eva‐juliane | CCSD

International audience. Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is impera...

Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

Archive ouverte | Towns, Clodagh | CCSD

International audience. The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramati...

The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited

Archive ouverte | Domenighetti, Cloé | CCSD

International audience. Abstract Background Two studies that examined the interaction between HLA‐DRB1 and smoking in Parkinson's disease (PD) yielded findings in opposite directions. Objective To perform a large‐sc...

Chargement des enrichissements...